Real‐life retrospective multicentre study to describe the use of dupilumab in paediatric patients with atopic dermatitis in Spain: Patient profile, effectiveness and safety

JEADV Clinical Practice, Journal Year: 2025, Volume and Issue: unknown

Published: Jan. 15, 2025

Abstract Background Dupilumab, inhibiting interleukin 4 and 13, is the first monoclonal antibody licensed for atopic dermatitis (AD) since 6 months of age. Objectives The study describes patients' profile, effectiveness safety in real life dupilumab adolescents with moderate‐severe AD children severe AD. Methods National, multicentre, observational, retrospective study, based on medical records' data extracted September 2023. Patients included were (12–17 years) (Eczema Area Severity Index [EASI] ≥ 16) (6–11 (EASI 21) at start therapy treated least 3 months. Results Among 211 analysed patients, treatment onset, 69.6% registered an Investigator's Global Assessment (IGA) = 4, a median Dermatology Life Quality (DLQI) 17, Peak Pruritus Numerical Rating Scale (PP‐NRS) 8. Atopic comorbidities present 69.7% patients. Overall, 97.1% patients had received systemic treatments before dupilumab, being oral corticosteroids (75.5%) most frequent. At 16 52 weeks, mean EASI percentage reductions from baseline −77.5% −84.7%, respectively, 71.8% 82.4% achieved ≤ 7. A total 70.5% 36.5% (16 weeks), 78% 48.4% (52 weeks) EASI‐75 EASI‐90, respectively. week 52, 70% 87% reduction ≥4 PP‐NRS points ≥6 DLQI points, No serious dupilumab‐related adverse events reported; 6.2% presented treatment‐related conjunctivitis 1.4% reported eosinophilia, but without discontinuation. Conclusions population pronounced disease burden as defined by signs, symptoms, quality life, comorbidities, treatments' use prior dupilumab. In short time demonstrated clinically relevant improvement acceptable continued over weeks.

Language: Английский

---

Comparative efficacy and safety of dupilumab versus newly approved biologics and JAKi in pediatric atopic dermatitis: A systematic review and network meta-analysis

PLoS ONE, Journal Year: 2025, Volume and Issue: 20(2), P. e0319400 - e0319400

Published: Feb. 24, 2025

Background The newly approved biologics and Janus kinase inhibitors (JAKi) for pediatric atopic dermatitis (AD) offer additional options clinical treatment. However, the efficacy safety differences compared to first biologic, dupilumab, remain unclear. Therefore, a network meta-analysis was conducted evaluate these identify potentially superior agents. Methods This systematic review PROSPERO-registered (CRD42024583658). Randomized controlled trials involving patients (<18 years old) published in PubMed, Embase, Web of Science, Cochrane Library up October 27, 2024 were searched screened. RevMan software utilized quality assessment, performed using R version 4.4.1. Efficacy measures included Investigator’s Global Assessment (IGA), Numeric Rating Scale Itch (NRS), Eczema Area Severity Index (EASI). results expressed as odds ratios (OR), while treatment rankings different interventions determined P-score. Result study 11 7 agents 2,352 patients. indicated that dupilumab (300 mg) showed better outcomes than placebo IGA-0/1 (OR = 4.68, 95% CI: 2.53–8.63), NRS-4 6.75, 3.85–11.86), all EASI outcomes. Tralokinumab may be most effective option alleviating pruritus (P-score NRS-4, 0.8447). Upadacitinib (30 best (P-score, 0.9414), EASI-90 0.9926), EASI-75 0.9707). Dupilumab had higher risk nasopharyngitis 2.15, 95%CI: 1.04–4.43). Compared both mg), adverse event rates with upadacitinib (15 mg 30 upper respiratory tract infection elevated baricitinib (2 4 tralokinumab mg). Conclusion AD remains substantial, other including upadacitinib, delgocitinib, also present certain advantages. Future necessitate further evaluation concerns.

Language: Английский

---

Novel drug delivery systems in topical treatment of atopic dermatitis

Naunyn-Schmiedeberg s Archives of Pharmacology, Journal Year: 2025, Volume and Issue: unknown

Published: March 13, 2025

Language: Английский

---

Paediatric Atopic Dermatitis: The Unexpected Impact on Life with a Specific Look at the Molecular Level

International Journal of Molecular Sciences, Journal Year: 2024, Volume and Issue: 25(9), P. 4778 - 4778

Published: April 27, 2024

Atopic dermatitis (AD) is a condition with multifactorial aetiology that affects the skin. It most often begins at preschool age and involves The disease’s main symptom intense itching, which occurs especially night child’s sleep, negatively impacting quality of life affected children and, consequently, their families. difficulty in resting during leads to many problems day, particularly behavioural disorders difficulties paying attention school, results learning impairment. unexpected symptoms AD are caused by pathophysiological processes include molecular pathways inflammatory cytokines such as IL-31, IL-1, IL-2, TNF-a, IL-6. Drawing on comprehensive review literature PubMed/MedLine, our offers an in-depth exploration both psychosocial impacts contribute this disorder.

Language: Английский

---

Revolutionizing Pediatric Dermatology: Dupilumab’s Impact on Atopic Dermatitis in Kids

American Journal of Life Science and Innovation, Journal Year: 2024, Volume and Issue: 3(1), P. 61 - 68

Published: June 4, 2024

Eczema, or atopic dermatitis, is a common, non-communicable, immune-mediated, inflammatory skin illness mainly affecting children. It chronic condition. causes mental health problems like anxiety, sadness, depression, hyperactivity, and obesity. the first ailment fifteenth non-fatal disease. The purpose of present research study was to evaluate Safety Effectiveness biological treatment for dermatitis using monoclonal antibodies against non-biological treatment, including antibiotics, immunosuppressants, demards, histamine antagonists corticosteroids. Patient information gathered from FDA-approved clinical trials. comparative analysis found that Biological therapies Dupilumab, Omalizumab, Ustekinumab improve symptoms disease control in dermatitis. Non-biological treatments may not be as effective. Early antibiotic exposure can increase infection vulnerability. Mild eczema infections require agents. Topical corticosteroids combined with Dupilumab effective Studies show improves quality life, making it better option than placebo. FDA recommends agents over immunosuppressants paediatrics improved immune results. trials showed dupilumab safe children moderate-to-severe reducing severity improving life young AD patients.

Language: Английский

---

Continued contribution to atopic innovation with dupilumab

Current Opinion in Pediatrics, Journal Year: 2024, Volume and Issue: 36(5), P. 537 - 541

Published: Aug. 8, 2024

Purpose of review Dupilumab is an emerging medication that has shown efficacy for multiple atopic conditions. This provides insight into the common conditions are treated, mechanism action, and continued innovation with medication. Recent findings There continues to be applicability dupilumab in treating a growing number Increasingly younger patient populations eosinophil based being approved this therapy. It also considered as additional option treatment patients who cannot tolerate oral therapy or have adverse effects from other agents. Patients more severe finally finding symptom stability while able reduce reliance on corticosteroids. young 6 months age benefited treatment. Summary As become prevalent, been successful inducing remission symptoms. Overall, it promising reducing burden disease severity well improving quality life affected children.

Language: Английский

---